COVID19: Ensuring the Quality, Resiliency, and Continuity of Breast Cancer Care During a Pandemic

Download this living slideset from the live Webinar on the management of patients with breast cancer during the COVID-19 pandemic and check back for updates as the situation evolves and new data and recommendations emerge.
Harold J. Burstein, MD, PhD
Hope S. Rugo, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.37 MB
Released: July 28, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Daiichi Sankyo, Inc.
Merck Sharp & Dohme Corp.

Related Content

In this downloadable slideset from Clinical Care Options (CCO) Nadia Harbeck, MD, PhD examines the evidence on checkpoint inhibitor therapy in TNBC.

person default Nadia Harbeck, MD, PhD Released: May 11, 2021

In this downloadable slideset from Clinical Care Options (CCO) Ian Krop, MD, PhD explores the evolving role of antibody-drug conjugates in TNBC.

Ian E. Krop, MD, PhD Released: May 11, 2021

Prof. Dr. Arndt Hartmann Released: April 9, 2021

Expert faculty review the use of targeted oral therapies for HR+/HER2- breast cancer in a webcast presented by Clinical Care Options (CCO)

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 8, 2021 Expired: April 7, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue